A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Phase of Trial: Phase II/III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms GATSBY
- Sponsors Chugai Pharmaceutical; Roche
- 14 Oct 2017 Status changed from discontinued to completed.
- 10 Jun 2017 Biomarkers information updated
- 05 May 2017 Status changed from completed to discontinued.